The efficacy of combination therapy using a type IA agent ( @entity5126 or @entity1818 ) and a type IB agent ( @entity2683 ) in suppressing inducible sustained @entity1165 was studied in 23 @entity1 undergoing serial drug testing with programmed stimulation. All @entity1 had @entity453 ( @entity453 ) with previous @entity583 and abnormal left ventricular function (mean ejection fraction 35%). Fifty-five percent of the @entity1 presented with @entity1163 or @entity1167 . In 19 @entity1 therapy had failed during empiric trials of 1 to 3 antiarrhythmic agents. All 23 @entity1 had inducible sustained @entity1165 (18 had uniform morphology sustained @entity1165 ( @entity1165 ) and 5 had @entity2224 [ @entity2224 ]) during control electrophysiologic study, and therapy had failed with a type IA agent and @entity2683 alone. The combination therapy of @entity2683 and the type IA agent prevented induction of any @entity1165 in 8 of 23 @entity1 . In 15 @entity1 , the combination significantly prolonged the @entity591 cycle length and reduced the symptoms associated with the induced @entity943 . @entity1 more likely to respond to the combination had shorter cycle lengths and polymorphic configuration of the control-induced @entity943 . The increased efficacy of the combination therapy could not be attributed to higher plasma drug levels for the combination, as there was no significant difference in plasma levels for each drug when given alone or in combination. Thus, the increased efficacy most likely reflects a synergistic electropharmacologic effect of the 2 agents.(ABSTRACT TRUNCATED AT 250 WORDS)

Efficacy of combination therapy with XXXX and a type IA agent for inducible @entity1165 secondary to @entity453 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachyarrhythmias', 'ventricular tachycardia', 'VT'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia'] @entity1163 :: ('MESH:D013575', 'Disease') :: ['syncope'] @entity2683 :: ('MESH:D008801', 'Chemical') :: ['mexiletine'] @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia'] @entity5126 :: ('MESH:D011802', 'Chemical') :: ['quinidine'] @entity2224 :: ('MESH:D014693', 'Disease') :: ['VF', 'ventricular fibrillation'] @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest'] @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease'] @entity1818 :: ('MESH:D011342', 'Chemical') :: ['procainamide']
@entity2683 :: (MESH:D008801,Chemical) :: ['mexiletine']
